News
KPRX
2.530
-1.17%
-0.030
Weekly Report: what happened at KPRX last week (0921-0925)?
Weekly Report · 09/28 10:16
Weekly Report: what happened at KPRX last week (0914-0918)?
Weekly Report · 09/21 10:17
Weekly Report: what happened at KPRX last week (0907-0911)?
Weekly Report · 09/14 10:22
Kiora Pharmaceuticals Bolsters Leadership in Clinical Development
TipRanks · 09/08 11:30
Weekly Report: what happened at KPRX last week (0831-0904)?
Weekly Report · 09/07 10:15
Weekly Report: what happened at KPRX last week (0824-0828)?
Weekly Report · 08/31 10:22
Weekly Report: what happened at KPRX last week (0817-0821)?
Weekly Report · 08/24 10:23
Kiora Pharmaceuticals: Global KIO-301 Partnerships and Advancing ABACUS-2 Study Support Buy Rating with Unchanged $12 Price Target
TipRanks · 08/21 15:35
Kiora Licenses KIO-301 Rights in South Korea
TipRanks · 08/19 11:27
Weekly Report: what happened at KPRX last week (0810-0814)?
Weekly Report · 08/17 10:24
Weekly Report: what happened at KPRX last week (0803-0807)?
Weekly Report · 08/10 10:19
Analysts Have Conflicting Sentiments on These Healthcare Companies: Joint (JYNT) and Kiora Pharmaceuticals (KPRX)
TipRanks · 08/08 16:30
Kiora Pharmaceuticals GAAP EPS of -$0.34 beats by $0.28
Seeking Alpha · 08/07 11:27
Weekly Report: what happened at KPRX last week (0727-0731)?
Weekly Report · 08/03 10:18
Weekly Report: what happened at KPRX last week (0720-0724)?
Weekly Report · 07/27 10:23
Weekly Report: what happened at KPRX last week (0713-0717)?
Weekly Report · 07/20 10:19
Weekly Report: what happened at KPRX last week (0706-0710)?
Weekly Report · 07/13 10:21
Weekly Report: what happened at KPRX last week (0629-0703)?
Weekly Report · 07/06 10:25
Weekly Report: what happened at KPRX last week (0622-0626)?
Weekly Report · 06/29 10:20
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Kiora Pharmaceuticals (KPRX) and MAIA Biotechnology, Inc. (MAIA)
TipRanks · 06/22 13:40
More
Webull provides a variety of real-time KPRX stock news. You can receive the latest news about KIORA PHARMACEUTICALS INC through multiple platforms. This information may help you make smarter investment decisions.
About KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.